Johnson & Johnson (J&J) is in discussions to purchase Protagonist Therapeutics, a move that would enhance their current collaboration, as reported by The Wall Street Journal (WSJ).

While a deal is not certain, the acquisition could significantly increase Protagonist’s current market value of more than $4bn.

According to FactSet, J&J, which holds 4% of Protagonist’s shares, is collaborating with the company on an oral immune disease treatment, targeting conditions such as plaque psoriasis and ulcerative colitis, and holds exclusive commercialisation rights.

The acquisition would also grant J&J access to rusfertide, a drug that demonstrated promise in late-stage trials for polycythaemia vera, a rare blood cancer, developed in partnership between Protagonist and Takeda Pharmaceutical.

This addition would bolster J&J’s cancer and immune drug portfolio.

Protagonist’s stock has surged more than 70% in 2025, propelled by positive trial outcomes for its treatments.

Since its initial public offering in 2016, the company’s shares have soared more than 450%.

Despite the potential acquisition size, it would be manageable for J&J, which has a market capitalisation nearing $460bn.

The healthcare giant is facing competition for its immune-disease drug Stelara and is seeking new products to mitigate the impact of sales losses due to patent expirations.

J&J has a history of strategic acquisitions, including the $15bn purchase of Intra-Cellular Therapies in January 2025.

In March, J&J Innovative Medicine announced that it is expanding its US footprint with a $55bn investment up to 2029.

In 2024, J&J expanded its biotech footprint with the $850m acquisition of Proteologix, which focuses on immune-mediated diseases.

“J&J in talks to acquire Protagonist Therapeutics” was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

 

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.